Rapid Medical™ Completes Initial Neurovascular Cases in the USA Following FDA Clearance of Its Active Access Solution
22 Julio 2024 - 9:16AM
Business Wire
DRIVEWIRE™ 24’s deflectable tip provides high-performance
navigation of catheters and devices in neuro and peripheral
vascular procedures
Rapid Medical™, a leading developer of advanced endovascular
devices, announces the first procedures in the USA with the
breakthrough deflectable access platform DRIVEWIRE 24 at the 2024
Society of NeuroInterventional Surgery’s (SNIS) 21st Annual
Meeting. With active technology, DRIVEWIRE articulates a wide range
of catheters for direct access to endovascular locations.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240722355520/en/
DRIVEWIRE 24 redefines interventional
access by providing an active deflectable tip that controls and
steers a range of catheters directly to the target vessels. Whereas
conventional access devices are reactive and rely on external
forces to reach their target, DRIVEWIRE's active technology selects
turns on-demand and handles the complexity of navigating the
vascular highway with ease. (Graphic: Business Wire)
“DRIVEWIRE addresses a major unmet need in the endovascular
space,” exclaims Dr. Shahram Majidi of Mount Sinai Health System in
New York City, NY. “It transforms access across a range of
procedures, from aneurysms to strokes and more. We’re always
looking for devices to make procedures faster, safer, less
expensive. My first experience with DRIVEWIRE suggests it could do
all of these.”
In the 2 cases completed by Dr. Majidi, DRIVEWIRE 24 navigated
the aspiration catheter directly to the M2 arterial occlusion for
first-pass excellent reperfusion. In the second case, DRIVEWIRE
navigated complex turns to place 2 flow diverters in a large,
multilobed aneurysm.
DRIVEWIRE provides high-performance intravascular steering.
Physicians control the direction and shape of the guidewire tip in
real time, eliminating the need to remove the wire to reshape it.
The device also features variable support to articulate a wide
range of micro and intermediate catheters without advanced forerun
or additional support devices. This results in precise navigation
via the most direct route through the neuro and peripheral
vasculature.
“With DRIVEWIRE, our design goal was to bring new levels of
access and control to the interventional suite while improving
best-in-class guidewires,” comments Giora Kornblau, Chief
Technology Officer at Rapid Medical. “When physicians are looking
for technologies that increase the clinical possibilities and
safety for the patient, we want Rapid to be the first place they
look.”
About Rapid Medical
Rapid Medical expands what’s possible in neurovascular treatment
by pioneering advanced interventional devices that treat ischemic
and hemorrhagic stroke. Utilizing proprietary manufacturing
techniques, Rapid Medical’s products are remotely adjustable and
fully visible. This enables physicians to respond in real-time to
the anatomy and tailor the approach to every patient for better
procedural outcomes. TIGERTRIEVER™ 13, 17, and 21, COMANECI™ and
COLUMBUS™/ DRIVEWIRE 14 are CE marked and FDA cleared. DRIVEWIRE 24
is FDA cleared. TIGERTRIEVER XL is also CE marked. More information
is available at www.rapid-medical.com.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240722355520/en/
Ronen Eckhouse +972-72-2503331 ronen@rapid-medical.com